Treatment regime for proliferative disorders
AssigneeOncolytics Biotech Inc.
InventorsMatthew C. Coffey, Bradley G. Thompson
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating or ameliorating a proliferative disorder in a subject. The method contains the steps of administering to the subject one dose of an immunosuppressive agent followed by administering to the subject one to five doses of a reovirus. The immunosuppressive agent is administered to the subject at least about 72 hours prior to administration of the reovirus. Also provided herein are methods for treating or ameliorating a proliferative disorder in a subject including the steps of administering to the subject an oncolytic virus and a B-cell modulating agent. Also provided are kits and pharmaceutical compositions containing an oncolytic virus and at least one B-cell modulating agent.
Claims43
A method of treating a proliferative disorder in a subject, the method comprising the steps of:
- a) administering to the subject one dose of an immunosuppressive agent;
- and
- b) administering to the subject one to five doses of a reovirus, wherein the immunosuppressive agent is administered at least about 72 hours prior to administration of the reovirus.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a proliferative disorder in a subject, the method comprising the steps of:
- a) administering to the subject an oncolytic virus;
- and
- b) administering to the subject at least one B-cell modulating, wherein the B-cell modulating agent selected from the group consisting of an anti-B-cell antibody, an anti-cytokine antibody and a small molecule selective modulator of B-cells.
A kit comprising an oncolytic virus and a B-cell modulating agent, wherein the B-cell modulating agent is selected from the group consisting of an anti-B-cell antibody, an anti-cytokine antibody and a small molecule selective modulator of B-cells.
Dependencies are inferred from the claim text.